Table 1. Baseline participant and disease characteristics.
| Participant characteristics | All participants | Participants with prior KS therapy | Participants without prior KS therapy* |
|---|---|---|---|
|
| |||
| Participants, n (%) | 32 (100) | 23 (72) | 9 (28) |
| Age, years, median (range) | 45 (28, 66) | 43 (28, 61) | 54 (38, 66) |
| Men, n (%) | 32 (100) | 23 (100) | 9 (100) |
| Race | |||
| White, n (%) | 16 (50) | 11 (48) | 5 (56) |
| Black, n (%) | 15 (47) | 12 (52) | 3 (33) |
| Not specified, n (%) | 1 (3) | 0 | 1 (11) |
| Hispanic/Latino, n (%) | 7 (22) | 6 (26) | 1 (11) |
| Disease characteristics | |||
| ACTG Tumor Stage | |||
| T1 | 26 | 21 | 5 |
| T0 | 6 | 2 | 4 |
| Number of prior systemic therapies, median (range) | 3 (1, 12) | 3 (1,12) | - |
| Prior radiation therapy, n (%) | 10 (31) | 8 (35) | 2 (22) |
| HIV characteristics | |||
| CD4+ cells/μL, median (range) | 274 (95, 1030) | 228 (95, 979) | 319 (101, 1030) |
| CD4+ 50-199 cells/μL, n (%) | 11 (34) | 8 (35) | 3 (33) |
| CD4+ 200-350 cells/μL, n (%) | 6 (19) | 4 (17) | 2 (22) |
| CD4+ >350 cells/μL, n (%) | 15 (47) | 11 (48) | 4 (44) |
| CD4+/CD8+ ratio, median (range) | 0.48 (0.13, 3.43) | 0.48 (0.13, 1.88) | 0.49 (0.15, 3.43) |
| CD4+/CD8+ ratio <1, n (%) | 25 (78) | 18 (78.3) | 7 (78) |
| Detectable plasma HIV RNA ≥20 copies/mL, n | 0 | 0 | 0 |
| Opportunistic prophylaxis, n (%) | 19 (59) | 15 (65) | 4 (44) |
*
Participants received pembrolizumab as the first systemic KS treatment.
T1 indicates KS with associated lymphedema, nodular or extensive involvement of the oropharynx, or visceral disease.
T0 indicates KS limited to the skin or minimal involvement of the oropharynx.
ACTG indicates AIDS Clinical Trials Group; KS, Kaposi sarcoma.